Exhibit 99.1
|
News Release AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 |
| Contact: | Barbara Brungess 610-727-7199 bbrungess@amerisourcebergen.com |
AMERISOURCEBERGEN NAMES DAVID W. NEU PRESIDENT OF
AMERISOURCEBERGEN DRUG CORPORATION
AMERISOURCEBERGEN DRUG CORPORATION
VALLEY FORGE, PA, April 4, 2011 — AmerisourceBergen Corporation (NYSE: ABC) today announced that
David W. Neu, 53, has been promoted to President of AmerisourceBergen Drug Corporation (ABDC), the
Company’s largest operating unit, effective immediately. Neu, a 29 year veteran of the Company,
was most recently Senior Vice President, Operations for ABDC. The role of President of
AmerisourceBergen Drug Corporation was previously held by Steven Collis, currently Executive Vice
President and Chief Operating Officer, and recently named to succeed David Yost as Chief Executive
Officer upon Yost’s retirement on July 1, 2011. In his new role, Neu will continue to report to
Steven Collis.
“Throughout his tenure at AmerisourceBergen, Dave has held several leadership roles within
ABDC, and he has been instrumental in both guiding its recent success, and positioning it for
future growth,” said Steven Collis. “Dave’s commitment to customers, suppliers, and associates and
his experience leading both sales and operational efforts will enable him to continue to drive
value for all of our stakeholders, and to take advantage of the opportunities that lie ahead.”
About AmerisourceBergen
AmerisourceBergen is one of the world’s largest pharmaceutical services companies serving the
United States, Canada and selected global markets. Servicing both healthcare providers and
pharmaceutical manufacturers in the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen’s service solutions range from pharmacy automation and pharmaceutical packaging
to reimbursement and pharmaceutical consulting services. With $78 billion in annual revenue,
AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people.
AmerisourceBergen is ranked #24 on the Fortune 500 list. For more information, go to
www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These statements are based on management’s
current expectations and are subject to uncertainty and change in circumstances. Among the factors
that could cause actual results to differ materially from those projected, anticipated or implied
are the following: changes in pharmaceutical market growth rates; the loss of one or more key
customer or supplier relationships; changes in customer mix; customer delinquencies, defaults or
insolvencies; supplier defaults or insolvencies; changes in pharmaceutical manufacturers’ pricing
and distribution policies or practices; adverse resolution of any contract or other dispute with
customers or suppliers; federal and state government enforcement initiatives to detect and prevent
suspicious orders of controlled substances and the diversion of controlled substances; qui tam
litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and
regulations governing the marketing, sale and purchase of pharmaceutical products or any related
litigation, including shareholder derivative lawsuits; changes in federal and state legislation or
regulatory action affecting pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical guidelines and/or labeling
for the pharmaceutical products we distribute, including certain anemia products; price inflation
in branded pharmaceuticals and price deflation in generics; greater or less than anticipated
benefit from launches of the generic versions of previously patented pharmaceutical products;
significant breakdown or interruption of our information technology systems; our inability to
continue to implement an enterprise resource planning (ERP) system to handle business and financial
processes and transactions (including processes and transactions relating to our customers and
suppliers) of AmerisourceBergen Drug Corporation operations and our corporate functions as intended
without functional problems, unanticipated delays and/or cost overruns; success of integration,
restructuring or systems initiatives; interest rate and foreign currency exchange rate
fluctuations; economic, business, competitive and/or regulatory developments in Canada, the United
Kingdom and elsewhere outside of the United States, including changes and/or potential changes in
Canadian provincial legislation affecting pharmaceutical product pricing or service fees or
regulatory action by provincial authorities in Canada to lower pharmaceutical product pricing and
service fees; the impact of divestitures or the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control; our inability to successfully complete
any other transaction that we may wish to pursue from time to time; changes in tax legislation or
adverse resolution of challenges to our tax positions; increased costs of maintaining, or
reductions in our ability to maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; and other economic, business, competitive, legal,
tax, regulatory and/or operational factors affecting our business generally. Certain additional
factors that management believes could cause actual outcomes and results to differ materially from
those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the
Company’s Annual Report on Form 10-K for the Fiscal Year Ended September 30, 2010 and elsewhere in
that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act
of 1934.
###